Ladenburg Thalmann Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $20

Benzinga Newsdesk www.benzinga.com Neutral 50.0%

Neg 0% Neu 50% Pos 0%

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $20.